BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26708291)

  • 1. The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.
    Macalou S; Robey RW; Jabor Gozzi G; Shukla S; Grosjean I; Hegedus T; Ambudkar SV; Bates SE; Di Pietro A
    Cell Mol Life Sci; 2016 May; 73(9):1927-37. PubMed ID: 26708291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.
    Hou YX; Li CZ; Palaniyandi K; Magtibay PM; Homolya L; Sarkadi B; Chang XB
    Biochemistry; 2009 Sep; 48(38):9122-31. PubMed ID: 19691360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
    Ozvegy C; Váradi A; Sarkadi B
    J Biol Chem; 2002 Dec; 277(50):47980-90. PubMed ID: 12374800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs.
    Zhang W; Yang Y; Dong Z; Shi Z; Zhang JT
    J Biol Chem; 2019 Dec; 294(52):20222-20232. PubMed ID: 31719146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
    Henriksen U; Gether U; Litman T
    J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
    Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
    Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
    Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.
    Ni Z; Bikadi Z; Cai X; Rosenberg MF; Mao Q
    Am J Physiol Cell Physiol; 2010 Nov; 299(5):C1100-9. PubMed ID: 20739628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport.
    Nakagawa R; Hara Y; Arakawa H; Nishimura S; Komatani H
    Biochem Biophys Res Commun; 2002 Dec; 299(4):669-75. PubMed ID: 12459192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
    Kuang YH; Patel JP; Sodani K; Wu CP; Liao LQ; Patel A; Tiwari AK; Dai CL; Chen X; Fu LW; Ambudkar SV; Korlipara VL; Chen ZS
    Biochem Pharmacol; 2012 Sep; 84(6):766-74. PubMed ID: 22750060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
    Shukla S; Robey RW; Bates SE; Ambudkar SV
    Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.
    Henriksen U; Fog JU; Litman T; Gether U
    J Biol Chem; 2005 Nov; 280(44):36926-34. PubMed ID: 16107343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
    González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
    J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of the Unique ABCG-Family NBD:NBD Interface Impacts Both Drug Transport and ATP Hydrolysis.
    Kapoor P; Briggs DA; Cox MH; Kerr ID
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.
    Valdameri G; Pereira Rangel L; Spatafora C; Guitton J; Gauthier C; Arnaud O; Ferreira-Pereira A; Falson P; Winnischofer SM; Rocha ME; Tringali C; Di Pietro A
    ACS Chem Biol; 2012 Feb; 7(2):322-30. PubMed ID: 22039929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP).
    Yang D; Kathawala RJ; Chufan EE; Patel A; Ambudkar SV; Chen ZS; Chen X
    Future Oncol; 2014 Aug; 10(11):1827-41. PubMed ID: 24295377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.